These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23660368)

  • 21. Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.
    Otová B; Václavíková R; Danielová V; Holubová J; Ehrlichová M; Horský S; Soucek P; Simek P; Gut I
    Eur J Pharm Sci; 2006 Dec; 29(5):442-50. PubMed ID: 17000091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
    Kuppens IE; Bosch TM; van Maanen MJ; Rosing H; Fitzpatrick A; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
    Lee CK; Choi JS
    Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
    Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
    Lee JH; Shin YJ; Kim HJ; Oh JH; Jang YP; Lee YJ
    Int J Pharm; 2011 May; 410(1-2):68-74. PubMed ID: 21421030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation.
    Nassar T; Attili-Qadri S; Harush-Frenkel O; Farber S; Lecht S; Lazarovici P; Benita S
    Cancer Res; 2011 Apr; 71(8):3018-28. PubMed ID: 21363913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The intravenous to oral switch of taxanes: strategies and current clinical developments.
    Vermunt MA; Bergman AM; der Putten EV; Beijnen JH
    Future Oncol; 2021 Apr; 17(11):1379-1399. PubMed ID: 33356545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
    van Waterschoot RA; Schinkel AH
    Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
    van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
    Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer.
    Patel K; Chowdhury N; Doddapaneni R; Boakye CHA; Godugu C; Singh M
    J Pharm Sci; 2015 Dec; 104(12):4417-4426. PubMed ID: 26372815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation.
    Yin YM; Cui FD; Mu CF; Choi MK; Kim JS; Chung SJ; Shim CK; Kim DD
    J Control Release; 2009 Dec; 140(2):86-94. PubMed ID: 19709639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
    Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
    de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
    Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells.
    Kamal MM; Nazzal S
    Int J Pharm; 2018 Jan; 536(1):187-198. PubMed ID: 29195916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.
    Oostendorp RL; Buckle T; Lambert G; Garrigue JS; Beijnen JH; Schellens JH; van Tellingen O
    Invest New Drugs; 2011 Oct; 29(5):768-76. PubMed ID: 20390333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
    Kuppens IE; Breedveld P; Beijnen JH; Schellens JH
    Cancer Invest; 2005; 23(5):443-64. PubMed ID: 16193644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
    Engels FK; Loos WJ; Mathot RA; van Schaik RH; Verweij J
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):569-79. PubMed ID: 17256132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
    Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
    Hendrikx JJ; Lagas JS; Song JY; Rosing H; Schellens JH; Beijnen JH; Rottenberg S; Schinkel AH
    Int J Cancer; 2016 Feb; 138(3):758-69. PubMed ID: 26297509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.